PIXIMUNE THERAPEUTICS
Live / Applied — Third extension granted (statement of use) (as of 17 Dec 2025)
What this means for you
Not registered yet, but its 26 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98102957
- Mark type
- Stylized text
- Filed
- 26 Jul 2023
- Published for opposition
- 30 Apr 2024
- Attorney of record
- Trevor P. Schmidt
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of retinal degeneration
- Class 042 — Scientific and technological services: Research and development in the field of pharmaceuticals for the treatment of retinal degeneration
Owner
- Piximune, Inc., Durham, NC, US
- Piximune, Inc., Durham, NC, US
Prosecution history
- 18 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Dec 2025 — SOU EXTENSION 3 GRANTED
- 17 Dec 2025 — SOU EXTENSION 3 FILED
- 17 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2025 — SOU EXTENSION 2 GRANTED
- 24 Jun 2025 — SOU EXTENSION 2 FILED
- 24 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Dec 2024 — SOU EXTENSION 1 GRANTED
- 23 Dec 2024 — SOU EXTENSION 1 FILED
- 23 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 25 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Apr 2024 — PUBLISHED FOR OPPOSITION